Market Overview

Allergan and Valeant Rally on News of Potential Three Way Deal With Pershing Square

Related AGN
Eli Lilly Beats on Q2 Earnings & Revs, Maintains View
Allergan, a Valeant Takeover Target, Plans 1,500 Job Cuts
Allergan to Slash 13% of its Global Workforce (Fox Business)

Shares of Allergen (NYSE: AGN) and Valeant Pharmaceuticals (NYSE: VRX) are moving higher, gaining 18 percent and 10.7 percent respectively after rumors the former, with the help of Bill Ackman, will acquire the latter for $45 billion, with one third being cash.

The official hostile bid is expected by Tuesday.

Ackman's Pershing Square has reported a 9.7 percent beneficial ownership in Allergan, which includes call options.

Pershing plans to buy $400 million of Valeant's Allergen stake at a 15 percent discount, and may have the right to end the pact if Valeant does not make hostile bid before May 2.

The deal is expected to create $25-$30 per share worth of synergies.

Posted-In: Bill Ackman Pershing SquareNews Hedge Funds M&A General

 

Most Popular

Related Articles (AGN + VRX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free